FindTrial
Sign In

The mechanism and risk stratification study of microvascular dysfunction in hypertrophic cardiomyopathy based on multi-modality CMR

The mechanism and risk stratification study of microvascular dysfunction in hypertrophic cardiomyopathy based on multi-modality CMR

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065361
Enrollment
Unknown
Registered
2022-11-03
Start date
2022-03-04
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertrophic cardiomyopathy

Interventions

case series:Nil

Sponsors

MR Center, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Confirmed to the diagnostic criteria; 2. Aged > 18 years old.

Exclusion criteria

Exclusion criteria: 1. Subjects with any disease that may cause the hypertrophy of left ventricle; 2. Subjects with coronary artery disease, valvular heart disease, congenital heart disease; 3. Subjects with history of heart surgery; 4. Subjects cannot finish CMR scan.

Design outcomes

Primary

MeasureTime frame
heart failure;sustained ventricular tachycardia;heart failure death;all-cause mortality;sudden death;Re-hospitalization due to heart failure;cardiac magnetic resonance;—

Secondary

MeasureTime frame
blood biochemistry;ECG;—

Countries

China

Contacts

Public ContactZhao Shihua

Department of MRI, Fuwai Hospital

cjr.zhaoshihua@vip.163.com+86 10 8832523

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026